進階搜尋


下載電子全文  
系統識別號 U0026-1708201211163600
論文名稱(中文) 台灣井水砷濃度與巴金森氏症的相關性
論文名稱(英文) The association between Arsenic in well water and Parkinson's Disease in Taiwan
校院名稱 成功大學
系所名稱(中) 環境醫學研究所
系所名稱(英) Institute of Environmental and Occupational Health
學年度 100
學期 2
出版年 101
研究生(中文) 黃琲淩
研究生(英文) Pei-Ling Wong
學號 S76995017
學位類別 碩士
語文別 英文
論文頁數 29頁
口試委員 指導教授-郭浩然
口試委員-張志欽
口試委員-林宙晴
召集委員-郭炤裕
中文關鍵字 井水砷  巴金森氏症  退化性神經疾病 
英文關鍵字 arsenic  degenerative neurological diseases 
學科別分類
中文摘要 在常見的漸進性神經退化疾病中,巴金森氏症僅次於失智症。巴金森氏症的病人常見的症狀包括休息時顫抖、肌肉僵直、動作緩慢。巴金森氏症的病理機轉和大腦製造多巴胺的黑質細胞退化有關。巴金森氏症目前原因不明, 而動物研究發現砷可以穿越腦血管障壁,沉澱在黑質區,破壞神經傳導物質的合成和釋放。由此推論,砷可以造成巴金森氏症疾病。然而到目前為止,只有細胞實驗和動物實驗提出砷會造成帕金森氏症。所以這篇研究主要是從流行學角度探討砷和巴金森氏症的相關性。
我們使用台灣健保資料庫收集2005年到2009年疾病代碼為332.0 或332.1並且使用藥物治療的病人.井水砷濃度則是採用台灣環保署針對台灣242鄉鎮井水所做的分析,依濃度高低分為2組。 我們使用SAS9.3軟體來進行分析,找出飲用井水中砷的濃度和帕金森氏症之間的相關性,並找出有無年齡和性別的差異。我們的結果顯示,巴金森氏症盛行率為每年十萬分之226人,發生率為每年十萬分之41.8人.男性得到巴金森氏症的機率比女性高.隨著年齡增加,得到巴金森氏症的機率越高,其中70-80歲為最高峰。而砷濃度較高地區的居民得到巴金森氏症的相對風險是其他地區居民的1.4倍,而95%信賴區間為(0.9-2.0),接近統計上的意義。
結論:雖然沒有達到統計上的意義,但砷濃度比較高地區居民有比較高的機會得到巴金森氏症。
英文摘要 introduction: Parkinson's disease (PD) is the second most common progressive neurodegenerative disease in Taiwan. It is associated with the desecration of dopamine-generated neurons in the substantial nigra in the brain, but actual etiology remains unknown. Some animal studies found that arsenic can pass through the blood brain barrier, aggregate in the substantia nigra area, and inhibit the synthesis and release of dopamine. Therefore, exposure to arsenic may be related to the occurrence of PD, but few epidemiological data are available on this issue. We conduct a study to evaluate the association between arsenic exposure through drinking water and the occurrence of PD in Taiwan.
Methods: We used the National Health Insurance Research Database to identify patients with PD from 2005 to 2009 and defined cases as those who had ICD-9-CM codes 332.0 or 332.1 among the diagnoses and received prescription of medicine for PD. Arsenic exposure was assessed using the survey of well water in 243 villages conducted by the Taiwanese government. We compare the occurrence of PD between villages within and outside the endemic areas of arsenic exposure to evaluate the association between the arsenic level in drinking water and the PD after adjusting for gender and age.
Results: The prevalence of PD was 226/100,000 and the incidence of PD was 41.8/100,000. Men had higher prevalence than women, and the peak age of late-type PD was 70-80 years old. The relative risk of people living in the endemic areas of arsenic exposure was 1.4 compared to those who did not live in the areas, and the 95% confidence interval was 0.9-2.0, indicating a marginal statistical significance.
Conclusion: People living in the endemic areas of arsenic exposure from drinking water had a higher risk of developing PD, but the increase did not reach statistical significance.
論文目次 中文摘要 1
Abstract 3
Acknowledgements 5
Table of Contents 6
Chapter 1 Introduction 7
Chapter 2 Literature Review 9
2-1 Parkinson’s disease epidemiology 9
2-2 The mechanism of Parkinson’s Disease 10
2-3 The etiology of Parkinson’s disease 11
2-4 The treatment of Parkinson’s disease 11
2-5 The Arsenic Toxicity 12
Chapter 3 The Purpose of this study 15
Chapter 4 Methods and Materials 16
Chapter 5 Results 19
Chapter 6 Discussion 23
Chapter 7 Conclusion 25
References 26

參考文獻 1. De Rijk MC, Tzourio C, Breteler MMB, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study: European community concerted action on the epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:10-15

2. Barnett-Cowan M, Dyde RT, Foxe SH, Moro E, Hutchison WD, Harris LR (June 2010). "Multisensory determinants of orientation perception in Parkinson's disease". Neuroscience 167 (4): 1138–50.

3. Rajesh Pahwa. The handbook of Parkinson's Disease , third edition. 2003
4. Stephen K. Van Den Eeden1, Caroline M. Tanner2, Allan L. Bernstein3, Robin D. Fross4, Amethyst Leimpeter1, Daniel A. Bloch5 and Lorene M. Nelson5. Incidence of Parkinson’s Disease: Variation by Age, Gender, and Race/Ethnicity. Am. J. Epidemiol. (2003) 157 (11): 1015-1022

5. Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology, 2001; 57: 1679-1686

6. Jordi Bové, Delphine Prou, Céline Perier, and Serge Przedborski. Toxin-Induced Models of Parkinson's Disease. NeuroRx. 2005 July; 2(3): 484–494.

7. Kim YS, Joh TH 2006. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 38:333-47.

8. Forno, Lysia S. MD. Neuropathology of Parkinson's Disease. Journal of Neuropathology & Experimental Neurology: March 1996 - Volume 55 - Issue 4 - ppg 259-272

9. Suzanne Lesage and Alexis Brice. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Human Molecular Genetics, 2009, Vol. 18, Review Issue 1 R48–R59

10. Fahn, Stanley (1996). "The Case of the Frozen Addicts: How the Solution of an Extraordinary Medical Mystery Spawned a Revolution in the Understanding and Treatment of Parkinson's Disease". The New England Journal of Medicine 335 (26): 2002.

11. Dinis-Oliveira RJ, Remião F, Carmo H, Duarte JA, Navarro AS, Bastos ML, Carvalho F. Paraquat exposure as an etiological factor of Parkinson's disease. Neurotoxicology. 2006 Dec;27(6):1110-22.

12. The National Collaborating Centre for Chronic Conditions, ed. (2006). "Symptomatic pharmacological therapy in Parkinson’s disease". Parkinson's Disease. London: Royal College of Physicians. pp. 59–100

13. Goldenberg MM (October 2008). "Medical management of Parkinson's disease". P & T 33 (10): 590–606.

14. Peter Riederer and Gerd Laux. MAO-inhibitors in Parkinson's Disease . Exp Neurobiol. 2011 March; 20(1): 1–17.

15. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012 Mar 14;3:CD006504.

16. Dan Douer and Martin S. Tallman. Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies. Journal of Clinical Oncology.2005

17. Jiin-Shuh Jean , Jochen Bundschuh , Chien-Jen Chen , How-Ran Guo , Chen-Wuing Liu , Tsair-Fuh Lin and Yen-Hua Chen. The Taiwan Crisis: a showcase of the global arsenic problem. CRC Press 2010 Pages 49–59

18. Niu S, Cao S, Shen E. The status of arsenic poisoning in China. In: Abernathy CO, Calderon RL, Chappell WR, eds. Arsenic: Exposure and Health Effects. Chapman & Hall, 1992:78-83.

19. Chowdhury UK, Biswas BK, Chowdhury R, Mandal BK, Samanta G, Basu GK et al. Arsenic groundwater contamination and sufferings of people in Bangladesh and West Bengal-India. In: Pan-Asia Pacific conference on fluoride and arsenic research: program and abstract book. Shenyang, China, 1999:27.

20. WHO (World Health Organization). Chapter 2: Chemical aspects. In: WHO Guidelines for Drinking Water Quality. Vol. 2: Health criteria and other supporting information. WHO Draft Geneva, Switzerland 1992:151-8.

21. 中央健康保險局網站公布資訊:網址http://www.nhi.gov.tw/
論文全文使用權限
  • 同意授權校內瀏覽/列印電子全文服務,於2017-09-07起公開。
  • 同意授權校外瀏覽/列印電子全文服務,於2017-09-07起公開。


  • 如您有疑問,請聯絡圖書館
    聯絡電話:(06)2757575#65773
    聯絡E-mail:etds@email.ncku.edu.tw